Clinical features and patency rates of Remedy® biodegradable peripheral stents

Basit Öğe Kaydı
dc.contributor.authorTiryakioglu, Selma Kenar
dc.contributor.authorTiryakioglu, Osman
dc.contributor.authorKarahan, Oguz
dc.contributor.authorDemirtas, Sinan
dc.contributor.authorGokalp, Fatih
dc.contributor.authorErkoc, Kamuran
dc.contributor.authorOzkan, Hakan
dc.date.accessioned2024-04-24T17:28:06Z
dc.date.available2024-04-24T17:28:06Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: The aim of this study was to investigate the mid-term results of Remedy (R) biodegradable stents, which have recently come into use for lower-extremity arterial occlusive disease. Methods: Sixty-five patients, who underwent surgical intervention in various cardiovascular surgery clinics throughout Turkey, were included in the study. The total number of stents used was 92. The mean age of the patients was 64.11 +/- 24.13 years (20-82), and 16 (24.6%) were female. The mean number of stents per patient was 1.42, and 70.7% of the lesions were TASC type A. Patients were followed for a mean of 32 months. Sixty-five patients underwent a control examination using either digital subtraction angiography or colour Doppler ultrasonography. In-stent restenosis was defined as >= 50% stenosis in the stent area in asymptomatic patients. The procedure was repeated if the degree of stenosis was >= 70%. Results: During the follow-up period, restenosis (>= 50% stenosis) was observed in seven patients (10.7%). The patency rate after secondary intervention was 100%, and there was no loss of limbs in any patient. Restenosis was observed in six patients with superficial femoral artery stents, and in one patient with a popliteal arterial stent. Conclusion: Our experience shows that Remedy (R) biodegradable peripheral stents were safe and effective in our cohort of patients, with acceptable patency rates.en_US
dc.identifier.doi10.5830/CVJA-2016-002
dc.identifier.endpage241en_US
dc.identifier.issn1995-1892
dc.identifier.issn1680-0745
dc.identifier.issue4en_US
dc.identifier.pmid26813981
dc.identifier.scopus2-s2.0-84988653867
dc.identifier.scopusqualityQ3
dc.identifier.startpage238en_US
dc.identifier.urihttps://doi.org/10.5830/CVJA-2016-002
dc.identifier.urihttps://hdl.handle.net/11468/20323
dc.identifier.volume27en_US
dc.identifier.wosWOS:000384800700016
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherClinics Cardive Publ Pty Ltden_US
dc.relation.ispartofCardiovascular Journal of Africa
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiodegradable Stenten_US
dc.subjectPeripheral Vascular Diseaseen_US
dc.subjectClinical Outcomesen_US
dc.subjectPatency Ratesen_US
dc.subjectRestenosisen_US
dc.titleClinical features and patency rates of Remedy® biodegradable peripheral stentsen_US
dc.titleClinical features and patency rates of Remedy® biodegradable peripheral stents
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu